🔗 Share this article

Given that the US proceeds with sweeping changes to its immunization recommendations, a particular individual appears in a surprising turn: Høeg, a Danish American physician and public health researcher who first made her name by questioning coronavirus vaccines during the pandemic and has zeroed in on potential fatalities after COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Schedule

Public health authorities were set to unveil radical changes to the pediatric immunization program earlier this month, bringing the US with the Danish national calendar, according to reports – a substantial departure that would place the US out of step with much of the international standard with no evidence for benefit. The announcement has been delayed until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the agency – and it points to a renewed priority upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for ending certain childhood vaccine recommendations in the US to become more like Denmark, a country with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

To date comments, she has continued to focus on vaccines – usually the purview of Dr. Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Background

Høeg has no obvious experience in drug development, regulation or administrative roles, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the necessary background” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in running a large organization. She is not an expert in drug approvals.”

Past directors of the center would “understand legal statutes and the science of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that former directors who led CBER have had.”

This division has an immense workload at the FDA, she stated.

“Many people just zeroes in on the novel medication approvals, but the generic program approves thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and each of these need to be managed,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a substantial leadership element to the position, which manages in excess of 5,000 employees. “It’s a enormous management job, if you do it right,” Woodcock concluded.

Agency Reaction and Controversial Policies

When asked about questions about Dr. Høeg's credentials and whether this selection signifies more teamwork among FDA leaders on vaccines, a press secretary responded that the “questions stem from incorrect assumptions”.

“This background aligns with the responsibilities of her role,” the official stated, noting the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new priority voucher program, a controversial rapid therapy clearance system that apparently troubled her predecessors. “How are these drugs being chosen for this expedited pathway? Who takes the decisions?” Howard questioned. “There is a lot of lack of transparency occurring at the agency right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed oversight of most medications, aside from vaccines.”

Public Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if problematic, history, Howard said. She published a analysis using non-validated crowd-sourced reports to assess the frequency of myocarditis following COVID-19 immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the current federal leadership featured altering rules for new vaccines and ending “non-essential” immunizations, she stated post-election on a online show. At the FDA, Høeg has according to sources suggested barring young men from obtaining COVID-19 vaccinations.

“She’s an all-around true believer who commences with her preconceived notions and tailors the evidence to fit the evidence in a very misleading, dishonest fashion,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|